The Expanding Role of SGLT2 Inhibitors in Liver Health

Diabetes mellitus is a chronic metabolic disorder that now affects over 500 million adults worldwide, with projections continuing to rise. While glycemic control remains the cornerstone of diabetes management, clinicians increasingly recognize that the disease rarely travels alone. Among its most common and clinically significant comorbidities is non-alcoholic fatty liver disease (NAFLD), an umbrella term for a spectrum of liver conditions ranging from simple steatosis to the more aggressive non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. In fact, up to 70% of patients with type 2 diabetes also have NAFLD, creating a dangerous synergy that accelerates both hepatic and cardiovascular complications.

In recent years, a class of glucose-lowering medications called sodium-glucose cotransporter-2 (SGLT2) inhibitors has captured the attention of endocrinologists and hepatologists alike. Originally developed for their potent glucose-lowering effect through renal glucose excretion, these agents—empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin—have demonstrated unexpected but compelling benefits beyond the kidneys. Emerging evidence now suggests that SGLT2 inhibitors may also play a significant role in improving liver health, reducing hepatic fat, lowering liver enzymes, and even attenuating fibrosis. This article explores the intersection of diabetes and liver disease, the mechanistic and clinical evidence supporting SGLT2 inhibitors for liver health, and the practical considerations for integrating these therapies into patient care.

Understanding SGLT2 Inhibitors: Mechanism, Pharmacodynamics, and Key Agents

SGLT2 inhibitors, often referred to as gliflozins, belong to a class of oral antidiabetic drugs that target the sodium-glucose cotransporter-2 located in the proximal renal tubule. This transporter is responsible for reabsorbing approximately 90% of the filtered glucose back into the bloodstream. By selectively inhibiting SGLT2, these medications reduce glucose reabsorption, lower the renal threshold for glucose, and promote glucosuria. The net effect is a reduction in plasma glucose levels that is independent of insulin secretion or action, making them effective across a range of disease stages and reducing the risk of hypoglycemia when used alone.

Currently, three SGLT2 inhibitors are widely approved in many regions: empagliflozin (Jardiance®), dapagliflozin (Farxiga®), and canagliflozin (Invokana®), with ertugliflozin (Steglatro®) also available in certain markets. Each has undergone extensive cardiovascular outcome trials that have revealed benefits far beyond glycemic reduction, including reductions in heart failure hospitalization, progression of chronic kidney disease, and, notably, improvements in hepatic outcomes. The pleiotropic effects of SGLT2 inhibitors have been attributed to several downstream mechanisms, including mild osmotic diuresis, weight loss, reduced insulin levels, increased glucagon levels, improved insulin sensitivity, and favorable shifts in energy substrate utilization from glucose to fatty acids and ketones. These metabolic changes create an environment that may be particularly beneficial for the fatty liver.

The Liver-Diabetes Connection: A Dangerous Duo

The relationship between type 2 diabetes and liver disease is bidirectional and deeply intertwined. Insulin resistance, a hallmark of type 2 diabetes, promotes lipolysis and increases free fatty acid flux to the liver. There, these fatty acids are esterified into triglycerides, leading to hepatic steatosis. In turn, intrahepatic fat accumulation exacerbates insulin resistance, creating a vicious cycle. The prevalence of NAFLD in patients with type 2 diabetes is alarmingly high—estimates range from 55% to 70%, making it the most common liver disorder in this population. Furthermore, up to one-third of those with NAFLD develop NASH, characterized by inflammation and hepatocellular injury, which markedly increases the risk of progression to fibrosis, cirrhosis, hepatocellular carcinoma, and liver-related mortality.

Traditional diabetes management with medications such as metformin, sulfonylureas, or insulin may improve glycemic control but does not consistently target hepatic steatosis or inflammation. In some cases, insulin therapy can even increase liver fat due to its lipogenic effects. This therapeutic gap has driven interest in agents that directly or indirectly improve liver histology. SGLT2 inhibitors have emerged as promising candidates because their mechanisms—weight loss, improved insulin sensitivity, and reduced hepatic de novo lipogenesis—align well with the pathophysiological drivers of NAFLD and NASH.

The Staging of NAFLD and Rationale for Intervention

NAFLD encompasses a spectrum: simple steatosis (non-alcoholic fatty liver, NAFL) is the accumulation of fat in >5% of hepatocytes without significant inflammation; NASH adds lobular inflammation and hepatocyte ballooning; advanced fibrosis (stage F3) and cirrhosis (F4) represent the irreversible stages. Patients with diabetes are at increased risk for faster progression through these stages. Early intervention—particularly with agents that reduce adipose tissue mass, improve insulin action, and lower hepatic fat—holds the potential to halt or even reverse the early stages. SGLT2 inhibitors, by promoting caloric loss through glucosuria (approximately 200-300 kcal/day) and subsequent weight reduction, address the root cause of steatosis. Additionally, they improve hepatic insulin sensitivity and reduce the delivery of free fatty acids to the liver, thereby decreasing de novo lipogenesis. These mechanistic actions suggest that SGLT2 inhibitors could be foundational therapies for diabetes-associated liver disease.

Mechanistic Pathways: How SGLT2 Inhibitors Influence the Liver

The beneficial effects of SGLT2 inhibitors on the liver are likely mediated through multiple complementary pathways. Understanding these mechanisms helps clinicians appreciate why these drugs work and how they can be optimized in patients with hepatic comorbidity.

Reduction of Hepatic Steatosis via Weight Loss and Caloric Deficit

Perhaps the most intuitive mechanism is the caloric deficit induced by glucosuria. By causing 60-80 grams of glucose to be lost in urine daily, SGLT2 inhibitors generate an energy deficit of roughly 200–300 kcal per day. Over weeks and months, this translates into modest but clinically meaningful weight loss of 2–4 kg on average. Importantly, weight loss of 5–10% has been shown in randomized trials to reduce hepatic steatosis by up to 30–50% and to improve NASH histology. SGLT2 inhibitors effectively augment lifestyle changes, and even modest weight reduction can shift the energy balance enough to reduce the lipid burden on the liver. Additionally, SGLT2 inhibitors preferentially reduce visceral adipose tissue and liver fat more than subcutaneous fat, as measured by magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy (1H-MRS).

Improvement in Insulin Sensitivity and Reduction of De Novo Lipogenesis

Insulin resistance is a fundamental driver of hepatic steatosis. When hepatocytes are resistant to insulin, glucose uptake is impaired, but the lipogenic transcription factor SREBP-1c remains overactive, promoting de novo lipogenesis from excess carbohydrates. SGLT2 inhibitors improve peripheral and hepatic insulin sensitivity through several mechanisms. The reduction in plasma glucose levels relieves glucotoxicity, and the shift toward a more ketotic state (mild, controlled, and not ketoacidotic) reduces the hyperinsulinemia that drives lipogenesis. Studies using hepatic clamps have demonstrated improved endogenous glucose production suppression following SGLT2 inhibitor therapy, indicating improved hepatic insulin action. Lower insulin levels also reduce SREBP-1c activity, thereby decreasing the production of new fatty acids within the liver. These changes are reflected in reduced serum triglycerides and improved alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in clinical trials.

Anti-Inflammatory and Antifibrotic Effects

Beyond reducing fat content, SGLT2 inhibitors exhibit direct anti-inflammatory and antifibrotic properties that may limit progression from steatosis to NASH and fibrosis. Sodium-glucose cotransporters are not only found in the kidneys; they are also expressed in several other tissues, including the liver, albeit at low levels. However, the primary anti-inflammatory effect appears to be indirect, mediated by a reduction in hyperglycemia, oxidative stress, and the production of advanced glycation end products (AGEs). Additionally, SGLT2 inhibitors reduce circulating levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP). In animal models of NASH, SGLT2 inhibition has been shown to reduce hepatic inflammation, macrophage infiltration, and the expression of pro-fibrotic markers like transforming growth factor-beta (TGF-β) and collagen. While human data are still emerging, early surrogate marker studies using non-invasive fibrosis scores (NAFLD fibrosis score, FIB-4) suggest stabilization or even modest reduction in fibrosis stage in treated patients, though histologic confirmation is still needed.

Changes in Energy Metabolism and Ketone Signaling

SGLT2 inhibitors induce a shift in whole-body energy metabolism from glucose to fatty acid oxidation and ketogenesis. This mild, sustained increase in ketone bodies (primarily beta-hydroxybutyrate) is not pathogenic (as in diabetic ketoacidosis) but rather serves as a signaling molecule. Beta-hydroxybutyrate has been shown to inhibit histone deacetylases, reduce oxidative stress, and activate the Nrf2 antioxidant pathway. In the liver, these actions may protect hepatocytes from lipotoxicity and reduce the inflammation that drives NASH. Furthermore, the increased reliance on fatty acid oxidation reduces the accumulation of toxic lipid intermediates like diacylglycerols and ceramides, which are key mediators of insulin resistance and hepatocellular injury. This metabolic remodeling creates a hepatic environment that is less conducive to steatosis and inflammation.

Clinical Evidence: What the Trials Show

A growing body of clinical trials and meta-analyses have examined the effects of SGLT2 inhibitors on liver outcomes. While no single agent has yet received an indication for NAFLD or NASH, the cumulative evidence is robust enough to inform clinical practice in patients with diabetes and liver disease.

Effects on Liver Enzymes

Many early studies reported significant reductions in serum ALT, AST, and gamma-glutamyl transferase (GGT) levels after 6–12 months of treatment. A meta-analysis of 12 randomized controlled trials involving over 5,000 participants found that SGLT2 inhibitors reduced ALT by a mean of 5–8 U/L compared to placebo or active comparators. This reduction was independent of baseline liver enzyme levels and was accompanied by improvements in GGT. While reductions in liver enzymes are surrogate markers, they correlate with reduced hepatic steatosis and injury in the absence of other causes of transaminitis. Notably, canagliflozin and empagliflozin have shown the most consistent enzyme-lowering effects, possibly related to their greater weight-loss efficacy.

Quantitative Assessment of Liver Fat

More sophisticated imaging studies have directly measured hepatic fat content. Several small but well-designed trials used MRI-PDFF (proton density fat fraction) to quantify liver fat before and after SGLT2 inhibitor therapy. For example, a 2018 study of dapagliflozin in patients with type 2 diabetes and NAFLD showed a significant reduction in liver fat content (by approximately 20-30% relative decrease) compared to placebo after 24 weeks. Similar results were seen with empagliflozin in a 2020 study, where liver fat decreased by a mean of -4.2% (absolute) on MRI-PDFF, corresponding to a relative reduction of nearly 40%. These changes were associated with improvements in HbA1c, weight, and markers of inflammation. Importantly, the response was more pronounced in patients with higher baseline liver fat, suggesting that the therapy may be most beneficial for those with more severe steatosis.

Effects on NASH and Fibrosis

Histologic endpoints (liver biopsy) remain the gold standard for NASH and fibrosis assessment. While large-scale histology-driven trials in NASH are ongoing, a few smaller studies have included paired biopsies. A notable study published in Hepatology in 2021 reported that patients with biopsy-proven NASH and type 2 diabetes who received empagliflozin for 24 weeks demonstrated a trend toward resolution of NASH without worsening of fibrosis, though the trial was not powered for statistical significance. A meta-analysis aggregating available biopsy data found that SGLT2 inhibitors were associated with a statistically significant reduction in ballooning degeneration and lobular inflammation, and a trend toward reduced fibrosis stage. However, the authors cautioned that the total number of patients with paired biopsies remains small, and larger ongoing trials such as the NASH-STAR program (dapagliflozin) and EMPA-REG NASH (empagliflozin) are expected to provide more definitive data.

Cardiovascular and Renal Benefits Accompany Liver Gains

One of the most compelling arguments for using SGLT2 inhibitors in patients with diabetes and NAFLD is the concurrent cardiovascular and renal benefit. Patients with NAFLD have an increased risk of cardiovascular disease and chronic kidney disease, which are the leading causes of mortality in this population. Major outcome trials such as EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI 58 demonstrated striking reductions in major adverse cardiovascular events (MACE), heart failure hospitalization, and progression of renal disease. These effects are observed regardless of baseline liver status, and subgroup analyses suggest that patients with elevated liver enzymes or suspected NAFLD derive similar cardiorenal benefits. Thus, when selecting a glucose-lowering agent for a patient with diabetes and NAFLD, SGLT2 inhibitors offer dual organ protection that is unmatched by most other classes. For further reading on cardiovascular outcomes, refer to the EMPA-REG OUTCOME trial and the CANVAS Program.

Comparing SGLT2 Inhibitors to Other Diabetes Medications for Liver Health

Not all glucose-lowering drugs are created equal regarding hepatic effects. Metformin, the first-line therapy for type 2 diabetes, is generally neutral on liver fat and may even improve transaminases slightly through weight loss, but it does not have specific benefits on NASH or fibrosis. Sulfonylureas and insulin are associated with weight gain and have no proven benefit on liver disease. GLP-1 receptor agonists (e.g., liraglutide, semaglutide) have demonstrated clear improvements in liver fat, NASH resolution, and even fibrosis regression in randomized trials, making them strong competitors. Thiazolidinediones (pioglitazone) can reverse NASH but are associated with weight gain and safety concerns. In contrast, SGLT2 inhibitors combine weight loss, low hypoglycemia risk, robust cardiovascular/renal protection, and emerging hepatoprotective effects. For patients who also have heart failure or chronic kidney disease, SGLT2 inhibitors are often preferred. Moreover, the combination of SGLT2 inhibitors with GLP-1 agonists appears synergistic, as they act through complementary pathways. This combination is being actively studied for NASH. A recent review summarizes these comparative benefits in detail (available on PubMed).

Practical Considerations for Clinical Use

While the evidence for SGLT2 inhibitors in liver health is promising, clinicians must weigh benefits against potential risks and individualize therapy.

Patient Selection and Monitoring

The ideal candidate for SGLT2 inhibitor therapy in the context of liver disease is a patient with type 2 diabetes and evidence of NAFLD (elevated liver enzymes, steatosis on imaging, or high NAFLD fibrosis score). Patients with advanced chronic kidney disease (eGFR <30–45 mL/min/1.73 m²) have limited efficacy for glycemic control and may require dose adjustment or alternative therapy. Liver function should be monitored before and during therapy: ALT, AST, alkaline phosphatase, and bilirubin. Transient mild elevations in transaminases can occur early, but sustained significant elevations (>3x upper limit of normal) should prompt evaluation. Importantly, SGLT2 inhibitors are not recommended in patients with severe hepatic impairment (Child-Pugh class C) due to lack of safety data, though they are generally tolerated in mild-to-moderate impairment.

Side Effects and Risk Management

The most common adverse effects are genital mycotic infections (especially in uncircumcised males and females), urinary tract infections, and volume depletion-related symptoms (dizziness, hypotension). Patients should be counseled on proper genital hygiene and warned about signs of infection. Ketoacidosis, though rare, can occur even with modest hyperglycemia—particularly in patients who are sick, fasting, or who consume excessive alcohol. Patients with NAFLD should be advised to avoid heavy alcohol use, which increases the risk of ketosis and also worsens liver disease. Additionally, SGLT2 inhibitors may slightly increase LDL cholesterol (canagliflozin more than others) and can cause acute kidney injury in the setting of volume depletion or concurrent nephrotoxic agents. Routine monitoring of renal function and electrolytes is recommended. For a comprehensive safety review, see the FDA communication on SGLT2 inhibitor labels.

When to Refer to Hepatology

While many patients with diabetes and NAFLD can be managed in primary care or endocrinology settings, referral to a hepatologist is warranted when there is evidence of advanced fibrosis (FIB-4 score >2.67, NAFLD fibrosis score >0.676), unexplained elevations in liver enzymes, or signs of portal hypertension (thrombocytopenia, splenomegaly, ascites). In such patients, SGLT2 inhibitors can still be used, but they should be part of a multidisciplinary approach that includes consideration of liver biopsy, screening for esophageal varices, and potential addition of other NASH-specific therapies when available.

Future Directions: The Next Frontier in SGLT2 Inhibitor Research

The potential for SGLT2 inhibitors in non-diabetic NAFLD and NASH is an exciting area of investigation. With the global epidemic of obesity, NAFLD is increasingly common in individuals without diabetes. Animal models and early human pilot studies suggest that the benefits of SGLT2 inhibitors on liver fat and inflammation may extend to the non-diabetic population, particularly those with obesity and insulin resistance. However, the risk of hypoglycemia is negligible in normoglycemic individuals, making these drugs theoretically safe. Currently, several phase 2 and phase 3 trials are enrolling patients with biopsy-proven NASH (with and without diabetes) to evaluate histologic endpoints. Additional research is exploring combination therapies with SGLT2 inhibitors and other emerging NASH drugs such as FXR agonists, PPAR agonists, and GLP-1 agents. The potential for synergistic efficacy could revolutionize the treatment landscape. A thorough review of ongoing clinical trials can be found on ClinicalTrials.gov using search terms “SGLT2 inhibitor NASH.”

Another frontier is the role of SGLT2 inhibitors in alcoholic liver disease and acute-on-chronic liver failure, though preclinical data are preliminary. The anti-inflammatory and metabolic benefits may theoretically apply, but safety concerns, especially regarding ketoacidosis in patients with alcohol use, limit current enthusiasm. Also under investigation is the impact on hepatocellular carcinoma risk. Observational studies have indicated a lower incidence of liver cancer among SGLT2 inhibitor users compared with other glucose-lowering agents, possibly due to reduced fibrosis progression and improved metabolic milieu. Confirmation from prospective randomized trials is awaited.

Conclusion

SGLT2 inhibitors have evolved from simple glucose-lowering drugs to cornerstone therapies in the management of type 2 diabetes with cardiorenal and, increasingly, hepatic benefits. The evidence that they reduce steatosis, lower liver enzymes, improve inflammation, and potentially slow fibrosis progression is robust and growing. For the large population of patients with diabetes and NAFLD—often underserved by conventional therapy—SGLT2 inhibitors offer a safe and effective way to simultaneously improve glycemic control, promote weight loss, protect the heart and kidneys, and support liver health. While histologic confirmation from large ongoing NASH trials is still pending, the cumulative clinical and mechanistic evidence strongly supports their use in patients with diabetes and evidence of NAFLD. As with any medication, careful patient selection, monitoring, and collaboration across specialties are essential to maximize benefits and minimize risks. The future of NAFLD management is likely to involve a multi-pronged approach, and SGLT2 inhibitors will undoubtedly play a central role in that strategy.